Page 66

Abril_2107

ARTÍCULO DE INVESTIGACIÓN Trombolisis endovenosa en ataque cerebrovascular isquémico - A. Soto et al 4. Doussoulin A, Rivas R, Sabelle C. Egresos hospitalarios por enfermedad cerebrovascular en el período 2001- 2010 en el Servicio de Salud Araucanía Sur. Rev Med Chile 2016; 144: 571-6. 5. Lavados PM, Díaz D, Jadue L, Olavarría VV, Cárcamo DA, Delgado I. Socioeconomic and Cardiovascular Variables Explaining Regional Variations in Stroke Mortality 474 in Chile: An Ecological Study. Neuroepidemiology 2011; 37: 45-51. 6. Soto A, Morales G, Pollak D, Jara V. Análisis de las consultas neurológicas en el Servicio de Urgencia de un hospital terciario. Rev Chil Neuro-Psiquiat 2016; 54 (2): 93-101. 7. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581- 7. 8. Hacke W, Kaste M, Bluhm E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. N Engl J Med 2008; 359 (13): 1317-29. 9. Feuerhake W, Chamorro H, Araya F. Activador del plasminógeno tisular intravenoso en el tratamiento del infarto cerebral agudo. Rev Med Chile 1999; 127: 814-9. 10. Figueroa-Reyes T, Sáez MD, Mansilla LE, Sánchez VR, Nogales-Gaete J, Delgado BI. Experiencia de Trombolisis sistematizada en infarto cerebral agudo en un hospital público de Chile. Rev Med Chile 2011; 139: 1118-27. 11. Soto A, Pollak D, Von Johnn A, Grandjean M, Riquelme A, García P, et al. Thrombolysis with alteplase in acute ischaemic stroke at Dr. Hernan Henriquez Hospital of Temuco-Chile. Póster WFN15-1543 Stroke. XXII World Congress of Neurology. Santiago, Chile, October 31 - November 5, 2015. 12. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial IST-3): a randomised controlled trial. Lancet 2012; 379: 2352-63. 13. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, et al; on behalf of the American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; STR.0000000000000086, published online before print December 22, 2015. 14. Balami JS, Hadley G, Sutherland BA, Karbalai H, Buchan AM. The exact science of stroke thrombolysis and the quiet art of patient selection. Brain 2013: 136; 3528- 53. 15. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-70. 16. Bamford J, Sandercock PA, Dennis MS, Burn J, Warlow CP. Classification and natural history of clinically identifiable subtypes of brain infarction. Lancet 1991; 337: 1521-6. 17. Lin K, Rapalino O, Law M, Babb JS, Siller KA, Pramanik BK. Accuracy of the Alberta Stroke Program Early CT Score during the First 3 Hours of Middle Cerebral Artery Stroke: Comparison of Noncontrast CT, CT Angiography Source Images, and CT Perfusion. AJNR Am J Neuroradiol 2008; 29: 931-6. 18. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-82. 19. Hacke W, Kaste M, Fieschi C, von Kummer R, Dávalos A,  Meier D, et al. Randomised double-blind placebo controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352(9136):1245-51. 20. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19 (5): 604-7. 21. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41. 22. Less KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703. 23. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke. JAMA 2013; 309 (23): 2480-8. 24. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 870-947. 25. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Rev Med Chile 2017; 145: 468-475


Abril_2107
To see the actual publication please follow the link above